Trials / Completed
CompletedNCT00002267
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 750 (planned)
- Sponsor
- Pharmacia · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this trial is to assess the safety and the relative benefit of rifabutin monotherapy in preventing or delaying the incidence of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200, as compared to placebo, and to assess if survival is prolonged in patients who receive rifabutin prophylaxis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifabutin |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
43 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00002267. Inclusion in this directory is not an endorsement.